Table 1.
Comparison of presenting features, initial treatment type, and outcomes between patients with t-AML and de novo AML
| Characteristic | t-AML (n=118) | De novo AML (n=237) |
P value |
|---|---|---|---|
| Age, years | |||
| Median (range) | 63.3 (29.5, 81) | 63.6 (25.6, 86.1) | .79 |
| WBC, × 109/L | |||
| Median (range) | 5 (0.4, 205) | 9.5 (0.4, 341.5) | .03 |
| Platelet, × 109/L | |||
| Median (range) | 43.5 (3, 378) | 55 (3, 658) | .01 |
| HGB, g/dL | |||
| Median (range) | 8.8 (3.8, 12.1) | 8.2 (2.8, 14.1) | .03 |
| BM blasts (%) | |||
| Median (range) | 42 (0, 96) | 52 (0, 98) | .01 |
| Race, white | 98(83.1%) | 206(86.9%) | .33 |
| FAB classification# | |||
| M0, M1, M2 | 41(41.4%) | 110(55.3%) | .03 |
| M3 | 8(8.1%) | 11(5.5%) | |
| M4 | 18(18.2%) | 37(18.6%) | |
| M5, M5a, M5b | 10(10.1%) | 22(11.1%) | |
| RAEB-T | 22(22.2%) | 19(9.5%) | |
| Unknown | 19 | 38 | |
| Performance status* | .53 | ||
| 0–1 | 85(72%) | 163(68.8%) | |
| >1 | 33(28%) | 74(31.2%) | |
| Cytogenetic risk | <.01 | ||
| Favorable | 13(11.4%) | 21(9.6%) | |
| Intermediate | 40(35.1%) | 137(62.8%) | |
| Poor | 61(53.5%) | 60(27.5%) | |
| Unknown | 4 | 19 | |
| Abnormal karyotype | 88(77.2%) | 109(50.0%) | <.01 |
| Del(5q)/-5, del(7q)/-7, and/or complex karyotype | 30(25.4%) | 21(8.9%) | <.01 |
| 11q23 abnormalities | 20 | 8 | <.01 |
| 11q23 rearrangements | 9 | 2 | .01 |
| Initial treatment regimens | .58 | ||
| HDAC | 79(66.9%) | 149(62.9%) | |
| Non-HDAC | 32(27.1%) | 67(28.3%) | |
| Non-Ara-c | 7(5.9%) | 21(8.9%) | |
| Complete remission | 62 (52.5%) | 144 (60.8%) | .14 |
| Median OS (rane), months | 8.7 (6.7, 13.4) | 10.2 (7.9, 12.9) | .17 |
| 5-year OS rate (range) | 15% (10%, 23%) | 20% (16%, 26%) | |
| Median RFS (range), months | 12.4 (8.7, 56.7) | 14.4 (11.5, 20.4) | .89 |
| 5-year RFS rate(range) | 30% (20%, 50%) | 30% (23%, 39%) |
AML, acute myeloid leukemia; WBC white blood cell; HGB, hemoglobin; BM, bone marrow.; FAB, French-American-British Classification; OS, overall survival; RFS, relapse free survival; HDAC, high dose a ra-C based regimen; RAEB-T, refractory anemia with excess blasts in transformation.
*
Eastern Cooperative Oncology Group;